{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:45Z","timestamp":1787002665510,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939) versus HLA-matched grafts (group B,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200927). Median age at diagnosis was 13 years, and 15 years (range 3\u201349 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status\/number of relapses at allo-SCT, or risk stratum. 9\/39 (23%) group A versus 2\/27 (7%) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7\/34 (21%) group A versus 9\/19 (47%) group B patients had developed chronic GvHD. In group A, 33\/39 (85%) versus 20\/27 (74%) group B patients died of disease and 1\/39 (3%) versus 1\/27 (4%) patients died of complications, respectively. Altogether 12\/66 (18%) patients survived in CR. Median EFS 24 months after allo-SCT was 20% in both groups, median OS was 27% (group A) versus 17% (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.02).\n                  <\/jats:p>","DOI":"10.1038\/s41409-020-01200-x","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T05:55:21Z","timestamp":1611899721000},"page":"1550-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-7337","authenticated-orcid":false,"given":"U.","family":"Thiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-4035","authenticated-orcid":false,"given":"S. J.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ranft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"von L\u00fcttichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Koscielniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-4835","authenticated-orcid":false,"given":"M.","family":"Ussowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-6213","authenticated-orcid":false,"given":"I.","family":"Kazantsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5726-9092","authenticated-orcid":false,"given":"T.","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-0075","authenticated-orcid":false,"given":"B.","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-7860","authenticated-orcid":false,"given":"U.","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Burdach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pcl.2010.01.001","volume":"57","author":"D Barrett","year":"2010","unstructured":"Barrett D, Fish JD, Grupp SA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am. 2010;57:47\u201366. https:\/\/doi.org\/10.1016\/j.pcl.2010.01.001. e-pub ahead of print 2010\/03\/24","journal-title":"Pediatr Clin North Am"},{"key":"1200_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/imt.10.20","volume":"2","author":"MN Bouchlaka","year":"2010","unstructured":"Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy. 2010;2:399\u2013418. https:\/\/doi.org\/10.2217\/imt.10.20. e-pub ahead of print 2010\/07\/20","journal-title":"Immunotherapy"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/2326-6066.CIR-16-0334","volume":"5","author":"EM Doorduijn","year":"2017","unstructured":"Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, et al. CD4+ T cell and NK cell interplay key to regression of MHC class Ilow tumors upon TLR7\/8 agonist therapy. Cancer Immunol Res. 2017;5:642\u201353. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0334. e-pub ahead of print 2017\/06\/24","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 2","key":"1200_CR4","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1038\/bmt.2015.100","volume":"50","author":"P Schlegel","year":"2015","unstructured":"Schlegel P, Feuchtinger T, Nitschke-Gerard C, Seidel UJ, Lang AM, Kyzirakos C, et al. Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing\u2019s sarcoma patients. Bone marrow Transplant. 2015;50(Suppl 2):S72\u2013S76. https:\/\/doi.org\/10.1038\/bmt.2015.100. e-pub ahead of print 2015\/06\/04","journal-title":"Bone marrow Transplant"},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.exphem.2012.07.004","volume":"40","author":"A Perez-Martinez","year":"2012","unstructured":"Perez-Martinez A, de Prada Vicente I, Fernandez L, Gonzalez-Vicent M, Valentin J, Martin R, et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012;40:882\u201391 e881. https:\/\/doi.org\/10.1016\/j.exphem.2012.07.004. e-pub ahead of print 2012\/07\/10","journal-title":"Exp Hematol"},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/imr.12157","volume":"258","author":"B Foley","year":"2014","unstructured":"Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014;258:45\u201363. https:\/\/doi.org\/10.1111\/imr.12157. e-pub ahead of print 2014\/02\/13","journal-title":"Immunol Rev"},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bcmd.2007.06.029","volume":"40","author":"L Ruggeri","year":"2008","unstructured":"Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84\u201390. https:\/\/doi.org\/10.1016\/j.bcmd.2007.06.029. e-pub ahead of print 2007\/10\/30","journal-title":"Blood Cells Mol Dis"},{"key":"1200_CR8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/annonc\/mdq703","volume":"22","author":"U Thiel","year":"2011","unstructured":"Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, et al. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol. 2011;22:1614\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdq703. e-pub ahead of print 2011\/01\/20","journal-title":"Ann Oncol"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321\u20137. https:\/\/doi.org\/10.1038\/nature25480. e-pub ahead of print 2018\/03\/01","journal-title":"Nature"},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138. https:\/\/doi.org\/10.1038\/nature12213. e-pub ahead of print 2013\/06\/19","journal-title":"Nature"},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ijc.28070","volume":"133","author":"JW Hodge","year":"2013","unstructured":"Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624\u201336. https:\/\/doi.org\/10.1002\/ijc.28070. e-pub ahead of print 2013\/02\/01","journal-title":"Int J Cancer"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-15-2550","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016;22:3182\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2550. e-pub ahead of print 2016\/01\/30","journal-title":"Clin Cancer Res"},{"key":"1200_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0062-8","author":"J Bae","year":"2018","unstructured":"Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018. https:\/\/doi.org\/10.1038\/s41375-018-0062-8. e-pub ahead of print 2018\/03\/01","journal-title":"Leukemia"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","volume":"65","author":"BC Worst","year":"2016","unstructured":"Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients\u2014the INFORM pilot study. Eur J Cancer. 2016;65:91\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.009. e-pub ahead of print 2016\/08\/02","journal-title":"Eur J Cancer"},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2011.08.020","volume":"18","author":"K Baird","year":"2012","unstructured":"Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012;18:698\u2013707. https:\/\/doi.org\/10.1016\/j.bbmt.2011.08.020. e-pub ahead of print 2011\/09\/08","journal-title":"Biol Blood Marrow Transplant"},{"key":"1200_CR16","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","volume":"28","author":"R Ladenstein","year":"2010","unstructured":"Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284\u201391. https:\/\/doi.org\/10.1200\/JCO.2009.22.9864. e-pub ahead of print 2010\/06\/16","journal-title":"J Clin Oncol"},{"key":"1200_CR17","doi-asserted-by":"publisher","first-page":"22741","DOI":"10.18632\/oncotarget.25228","volume":"9","author":"SJ Schober","year":"2018","unstructured":"Schober SJ, von Luettichau I, Wawer A, Steinhauser M, Salat C, Schwinger W, et al. Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. Oncotarget. 2018;9:22741\u20138. https:\/\/doi.org\/10.18632\/oncotarget.25228. e-pub ahead of print 2018\/06\/02","journal-title":"Oncotarget"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1023\/A:1026539908115","volume":"11","author":"S Burdach","year":"2000","unstructured":"Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-cell transplant programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451\u201362.","journal-title":"Ann Oncol"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12810","volume":"165","author":"P Lang","year":"2014","unstructured":"Lang P, Teltschik HM, Feuchtinger T, Muller I, Pfeiffer M, Schumm M, et al. Transplantation of CD3\/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol. 2014;165:688\u201398. https:\/\/doi.org\/10.1111\/bjh.12810. e-pub ahead of print 2014\/03\/05","journal-title":"Br J Haematol"},{"key":"1200_CR20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.bbmt.2017.08.012","volume":"23","author":"NJ Llosa","year":"2017","unstructured":"Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127\u201336. https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.012. e-pub ahead of print 2017\/08\/16","journal-title":"Biol Blood Marrow Transplant"},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/pbc.25042","volume":"61","author":"M Rasper","year":"2014","unstructured":"Rasper M, Jabar S, Ranft A, Jurgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014;61:1382\u20136. https:\/\/doi.org\/10.1002\/pbc.25042. e-pub ahead of print 2014\/04\/15","journal-title":"Pediatr Blood Cancer"}],"updated-by":[{"DOI":"10.1038\/s41409-021-01421-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01200-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T12:05:18Z","timestamp":1628683518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01200-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01200-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-021-01421-8","URL":"https:\/\/doi.org\/10.1038\/s41409-021-01421-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}